[{"edinetCode":"E00984","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":14670.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":212394000.0,"sharesOwendPercent":0.2996,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":31.5,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2017\/6\/19","stockCode":4568,"accountingYear":"第12期（自　2016年４月１日　至　2017年３月31日）","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00984","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50000,"settlementDate":"2022\/3\/31","submitterName":"第一三共株式会社","submitterNameEnglish":"DAIICHI SANKYO COMPANY, LIMITED","submitterNameKana":"ダイイチサンキョウカブシキガイシャ","location":"中央区日本橋本町三丁目５番１号","industory":"医薬品","corporateNumber":1010000000000.0},{"edinetCode":"E00984","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":14446.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":262659000.0,"sharesOwendPercent":0.4055,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":38.6,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2018\/6\/18","stockCode":4568,"accountingYear":"第13期（自　2017年４月１日　至　2018年３月31日）","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00984","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50000,"settlementDate":"2022\/3\/31","submitterName":"第一三共株式会社","submitterNameEnglish":"DAIICHI SANKYO COMPANY, LIMITED","submitterNameKana":"ダイイチサンキョウカブシキガイシャ","location":"中央区日本橋本町三丁目５番１号","industory":"医薬品","corporateNumber":1010000000000.0},{"edinetCode":"E00984","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":14887.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":284766000.0,"sharesOwendPercent":0.4395,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":2088050000000.0,"currentAssets":1393180000000.0,"fixedAsset":null,"tangibleFixedAssets":229085000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":838346000000.0,"currentLiabilities":384544000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":50000000000.0,"capitalSurplus":94633000000.0,"accumulatedEarnings":1152810000000.0,"treasuryStock":-162964000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":364605000000.0,"grossProfit":null,"sgaExpenses":277695000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":35.4,"roe":null,"cashFlowFromOperatingActivities":92033000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-142520000000.0,"cashFlowFromFinancialActivities":-66203000000.0,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2019\/6\/17","stockCode":4568,"accountingYear":"第14期（自　2018年４月１日　至　2019年３月31日）","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00984","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50000,"settlementDate":"2022\/3\/31","submitterName":"第一三共株式会社","submitterNameEnglish":"DAIICHI SANKYO COMPANY, LIMITED","submitterNameKana":"ダイイチサンキョウカブシキガイシャ","location":"中央区日本橋本町三丁目５番１号","industory":"医薬品","corporateNumber":1010000000000.0},{"edinetCode":"E00984","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":2060970000000.0,"currentAssets":1348120000000.0,"fixedAsset":null,"tangibleFixedAssets":255043000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":806051000000.0,"currentLiabilities":326631000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":50000000000.0,"capitalSurplus":94633000000.0,"accumulatedEarnings":1174780000000.0,"treasuryStock":-162962000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":87899000000.0,"grossProfit":null,"sgaExpenses":63161000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":77574000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":5583000000.0,"cashFlowFromFinancialActivities":-61300000000.0,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/6","stockCode":4568,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00984","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50000,"settlementDate":"2022\/3\/31","submitterName":"第一三共株式会社","submitterNameEnglish":"DAIICHI SANKYO COMPANY, LIMITED","submitterNameKana":"ダイイチサンキョウカブシキガイシャ","location":"中央区日本橋本町三丁目５番１号","industory":"医薬品","corporateNumber":1010000000000.0},{"edinetCode":"E00984","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":297394000.0,"sharesOwendPercent":0.459,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":2043400000000.0,"currentAssets":1358610000000.0,"fixedAsset":null,"tangibleFixedAssets":241948000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":770436000000.0,"currentLiabilities":333178000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":50000000000.0,"capitalSurplus":94737000000.0,"accumulatedEarnings":1200180000000.0,"treasuryStock":-162805000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":177105000000.0,"grossProfit":null,"sgaExpenses":130454000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":102282000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":21321000000.0,"cashFlowFromFinancialActivities":-63878000000.0,"changesInCashAndCashEquivalents":null,"列1":"q2r","submitDate":"2019\/11\/6","stockCode":4568,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00984","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50000,"settlementDate":"2022\/3\/31","submitterName":"第一三共株式会社","submitterNameEnglish":"DAIICHI SANKYO COMPANY, LIMITED","submitterNameKana":"ダイイチサンキョウカブシキガイシャ","location":"中央区日本橋本町三丁目５番１号","industory":"医薬品","corporateNumber":1010000000000.0},{"edinetCode":"E00984","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":2089750000000.0,"currentAssets":1391760000000.0,"fixedAsset":null,"tangibleFixedAssets":242458000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":759468000000.0,"currentLiabilities":322643000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":50000000000.0,"capitalSurplus":94724000000.0,"accumulatedEarnings":1249970000000.0,"treasuryStock":-162788000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":256280000000.0,"grossProfit":null,"sgaExpenses":208232000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":140799000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":33384000000.0,"cashFlowFromFinancialActivities":-89026000000.0,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/6","stockCode":4568,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00984","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50000,"settlementDate":"2022\/3\/31","submitterName":"第一三共株式会社","submitterNameEnglish":"DAIICHI SANKYO COMPANY, LIMITED","submitterNameKana":"ダイイチサンキョウカブシキガイシャ","location":"中央区日本橋本町三丁目５番１号","industory":"医薬品","corporateNumber":1010000000000.0},{"edinetCode":"E00984","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":15348.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":310221000.0,"sharesOwendPercent":0.4787,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":2105620000000.0,"currentAssets":1384120000000.0,"fixedAsset":null,"tangibleFixedAssets":247053000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":799344000000.0,"currentLiabilities":351071000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":50000000000.0,"capitalSurplus":94633000000.0,"accumulatedEarnings":1241600000000.0,"treasuryStock":-162519000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":343206000000.0,"grossProfit":null,"sgaExpenses":302320000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":37.3,"roe":null,"cashFlowFromOperatingActivities":196601000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":81673000000.0,"cashFlowFromFinancialActivities":-91637000000.0,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2020\/6\/15","stockCode":4568,"accountingYear":"第15期（自　2019年４月１日　至　2020年３月31日）","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00984","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50000,"settlementDate":"2022\/3\/31","submitterName":"第一三共株式会社","submitterNameEnglish":"DAIICHI SANKYO COMPANY, LIMITED","submitterNameKana":"ダイイチサンキョウカブシキガイシャ","location":"中央区日本橋本町三丁目５番１号","industory":"医薬品","corporateNumber":1010000000000.0},{"edinetCode":"E00984","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":2063190000000.0,"currentAssets":1317800000000.0,"fixedAsset":null,"tangibleFixedAssets":247867000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":747077000000.0,"currentLiabilities":304649000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":50000000000.0,"capitalSurplus":94633000000.0,"accumulatedEarnings":1250760000000.0,"treasuryStock":-161849000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":82211000000.0,"grossProfit":null,"sgaExpenses":71790000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":55877000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-70848000000.0,"cashFlowFromFinancialActivities":-26074000000.0,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/6","stockCode":4568,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00984","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50000,"settlementDate":"2022\/3\/31","submitterName":"第一三共株式会社","submitterNameEnglish":"DAIICHI SANKYO COMPANY, LIMITED","submitterNameKana":"ダイイチサンキョウカブシキガイシャ","location":"中央区日本橋本町三丁目５番１号","industory":"医薬品","corporateNumber":1010000000000.0},{"edinetCode":"E00984","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":310860000.0,"sharesOwendPercent":0.4793,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":2079760000000.0,"currentAssets":1327980000000.0,"fixedAsset":null,"tangibleFixedAssets":246810000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":746039000000.0,"currentLiabilities":296638000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":50000000000.0,"capitalSurplus":94633000000.0,"accumulatedEarnings":1270650000000.0,"treasuryStock":-161383000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":168573000000.0,"grossProfit":null,"sgaExpenses":148615000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":111800000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-13559000000.0,"cashFlowFromFinancialActivities":-69279000000.0,"changesInCashAndCashEquivalents":null,"列1":"q2r","submitDate":"2020\/11\/6","stockCode":4568,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00984","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50000,"settlementDate":"2022\/3\/31","submitterName":"第一三共株式会社","submitterNameEnglish":"DAIICHI SANKYO COMPANY, LIMITED","submitterNameKana":"ダイイチサンキョウカブシキガイシャ","location":"中央区日本橋本町三丁目５番１号","industory":"医薬品","corporateNumber":1010000000000.0},{"edinetCode":"E00984","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":2051190000000.0,"currentAssets":1281960000000.0,"fixedAsset":null,"tangibleFixedAssets":252350000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":759876000000.0,"currentLiabilities":313298000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":50000000000.0,"capitalSurplus":94576000000.0,"accumulatedEarnings":1268900000000.0,"treasuryStock":-201377000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":256412000000.0,"grossProfit":null,"sgaExpenses":229275000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":132252000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":104854000000.0,"cashFlowFromFinancialActivities":-138900000000.0,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/2\/5","stockCode":4568,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00984","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50000,"settlementDate":"2022\/3\/31","submitterName":"第一三共株式会社","submitterNameEnglish":"DAIICHI SANKYO COMPANY, LIMITED","submitterNameKana":"ダイイチサンキョウカブシキガイシャ","location":"中央区日本橋本町三丁目５番１号","industory":"医薬品","corporateNumber":1010000000000.0},{"edinetCode":"E00984","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":16033.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":911345000.0,"sharesOwendPercent":0.4756,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":2085180000000.0,"currentAssets":1268420000000.0,"fixedAsset":null,"tangibleFixedAssets":265281000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":813125000000.0,"currentLiabilities":353571000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":50000000000.0,"capitalSurplus":94494000000.0,"accumulatedEarnings":1277330000000.0,"treasuryStock":-261252000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":338289000000.0,"grossProfit":null,"sgaExpenses":333079000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":82.3,"roe":null,"cashFlowFromOperatingActivities":192207000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-39246000000.0,"cashFlowFromFinancialActivities":-202433000000.0,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2021\/6\/21","stockCode":4568,"accountingYear":"第16期（自　2020年４月１日　至　2021年３月31日）","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00984","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50000,"settlementDate":"2022\/3\/31","submitterName":"第一三共株式会社","submitterNameEnglish":"DAIICHI SANKYO COMPANY, LIMITED","submitterNameKana":"ダイイチサンキョウカブシキガイシャ","location":"中央区日本橋本町三丁目５番１号","industory":"医薬品","corporateNumber":1010000000000.0},{"edinetCode":"E00984","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":2062470000000.0,"currentAssets":1233700000000.0,"fixedAsset":null,"tangibleFixedAssets":276362000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":782371000000.0,"currentLiabilities":332771000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":50000000000.0,"capitalSurplus":null,"accumulatedEarnings":1157950000000.0,"treasuryStock":-37921000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":85152000000.0,"grossProfit":null,"sgaExpenses":79117000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-30092000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":30008000000.0,"cashFlowFromFinancialActivities":-29278000000.0,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/8\/5","stockCode":4568,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00984","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50000,"settlementDate":"2022\/3\/31","submitterName":"第一三共株式会社","submitterNameEnglish":"DAIICHI SANKYO COMPANY, LIMITED","submitterNameKana":"ダイイチサンキョウカブシキガイシャ","location":"中央区日本橋本町三丁目５番１号","industory":"医薬品","corporateNumber":1010000000000.0},{"edinetCode":"E00984","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":938544000.0,"sharesOwendPercent":0.4897,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":2110730000000.0,"currentAssets":1270180000000.0,"fixedAsset":null,"tangibleFixedAssets":285025000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":798501000000.0,"currentLiabilities":336046000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":50000000000.0,"capitalSurplus":null,"accumulatedEarnings":1185470000000.0,"treasuryStock":-37555000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":172559000000.0,"grossProfit":null,"sgaExpenses":163616000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":31467000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":188563000000.0,"cashFlowFromFinancialActivities":-52751000000.0,"changesInCashAndCashEquivalents":null,"列1":"q2r","submitDate":"2021\/11\/8","stockCode":4568,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00984","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50000,"settlementDate":"2022\/3\/31","submitterName":"第一三共株式会社","submitterNameEnglish":"DAIICHI SANKYO COMPANY, LIMITED","submitterNameKana":"ダイイチサンキョウカブシキガイシャ","location":"中央区日本橋本町三丁目５番１号","industory":"医薬品","corporateNumber":1010000000000.0},{"edinetCode":"E00984","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":2163470000000.0,"currentAssets":1310640000000.0,"fixedAsset":null,"tangibleFixedAssets":296423000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":832251000000.0,"currentLiabilities":355195000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":50000000000.0,"capitalSurplus":null,"accumulatedEarnings":1191430000000.0,"treasuryStock":-37558000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":264498000000.0,"grossProfit":null,"sgaExpenses":253573000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":101137000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":172520000000.0,"cashFlowFromFinancialActivities":-82637000000.0,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2022\/2\/4","stockCode":4568,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00984","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":50000,"settlementDate":"2022\/3\/31","submitterName":"第一三共株式会社","submitterNameEnglish":"DAIICHI SANKYO COMPANY, LIMITED","submitterNameKana":"ダイイチサンキョウカブシキガイシャ","location":"中央区日本橋本町三丁目５番１号","industory":"医薬品","corporateNumber":1010000000000.0}]